genmab danish biotechnology company founded february florian schönharting time managing director bankinvest biomedical venture company based copenhagen denmark internationally operates subsidiaries genmab bv utrecht netherlands genmab us inc princeton usa genmab kk tokyo japan dual listed company shares traded copenhagen stock exchange nasdaq global select market company approved antibodies monoclonal bispecific used marketed products covering cancer indications autoimmune proprietary marketed partners marketed partners furthermore genmab partners whole range antibody programs building genmab technologies clinical preclinical development cancer autoimmune diseasesgenmab several late stage clinical programs tisotumab vedotin cervical cancer ovarian cancer solid tumors epcoritamab bcell nonhodgkin lymphoma relapsedrefractory follicular lymphomathe partners among others clinical programs daratumumab nonmm blood cancers amivantamab gastric cancer esophageal cancer factor viii mimetic bispecific antibody haemophilia inclacumab voc sickle cell disease teprotumumab diffuse cutaneous systemic sclerosiscitation needed genmabs technology licensed medarex create fully human high affinity antibodies using transgenic mice antibodies less likely elicit allergic reaction side effects compared types manmade antibodies containing animal proteins igg antibodies produced human proteins technology called humabmouse technology one benefit using type technology need humanization complicated genetic engineering make antibody fit humans cuts expenses time spent developing generated within months selected bind specific antigens tumor cells infectious agents genmab also developed technology called unibody used make smaller antibodies contrast traditional full sized monoclonal antibody smaller size allows better distribution larger target areas like tumors unibody bind one site elicit harmful immune response binding two sites overactivating cell growth kill target cells rather silences inhibits thus used treat certain cancers inflammations allergies asthmas killing cell technology modifies human antibody normally considered inert elicit immune response however also unstable fall apart easily makes unsuitable therapeutic use genmab changes shape antibody eliminating hinge part antibody creates shape halves antibody creating smaller version known unibody smaller version bind one site stimulate cancer cells genmab founded european spinoff american biotech company medarex february danish investment firm bankinvest florian schönharting provided seed investment company start copenhagen like medarex genmab began work producing monoclonal antibodies lifethreatening debilitating diseases rising quickly biotech world genmab attracted many investors especially venture capital firms company went public october earning dkk billion second public offering january yielding dkk million companys initial rd location ninestory building utrecht science park netherlands replaced rd center also utrecht june new facility capacity plans set afoot build adjacent connected medarex genmab come back together drug development partnership highlighted manufacturing deficit clinical development expertise genmab relative biotechnology industry organization bio long island life sciences initiative honored genmab james watson helix saw company purchasing antibody manufacturing plant brooklyn park minnesota pdl biopharma plans retain employees however company ran financial trouble originating several quarters decision sell facility reached late genmab started producing development scale batches world experiencing financial crisis whole glaxosmithkline decided exit oncology impacted codevelopment ofatumumab oncologydirected tandem sale plant company reorganized planned dismiss selling facility though proved difficult due large part global financial crisis genmab decided simply writeoff entire facility companys balance sale facility baxter came february following failed strategy inhousing manufacturing genmab chose thereafter completely outsource manufacturing conduct clinical companys first product arzerra ofatumumab reached us market refractory chronic lymphocytic verification lisa n drakeman phd vice president medarex wife donald drakeman medarexs ceo president time drakeman one genmabs cofounders appointed chief executive officer ceo company upon incorporation also joining board drakeman remained ceo announced jan van de winkel cofounder firm appointed president ceo since company started genmabs chief scientific officer cso concurrently served head research president van de winkel remained ceo van de winkel scientist produced publications amgen may genmab entered sublicense agreement amgen would gain rights antibodies october replaced direct license agreement amgen retained exclusive commercialization options products phase ii amgen also expanded agreement new antibody program targeting additional disease targets amgen discontinued development antibody amg psoriasis rheumatoid arthritis based disappointing results recent clinical studies amgen exploring options maximize value asset time internal development lead indication planned glaxosmithkline december genmab entered deal glaxosmithkline codevelop commercialize drug could used treatment positive bcell chronic lymphocytic leukemia follicular nonhodgkin lymphoma rheumatoid arthritis indications agreement gave genmab license fee dkk million million gsk bought shares genmab dkk million million potential value agreement could dkk billion billion milestones reached commercial success reached fields cancer autoimmune inflammatory intention glaxosmithkline exit oncology disagreement around milestones reached financial difficulties genmab led renegotiation partnership resulting immediate million payment glaxosmithkline future financial licensing concessions part addition genmab collaborations roche monoclonal antibody directed collaboration terminated status february httpsenwikipediaorgwikigenmab